Abstract Library

#3711 Evaluation of unreimbursed costs in the UK through utilisation of home administration of lanreotide autogel (LAN) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Homecare is an established delivery method utilised by the UK NHS. In the UK, patients with GEP-NETs on a stable dose of LAN can be trained for self or partner administration or can be administered by a homecare nurse. Both methods remove LAN related activity in an acute setting, negating costs to the provider. The National Tariff payment system is a set of prices to help the NHS deliver value to patients. The price, as set out in the 2022/23 National Tariff workbook, for a single professional follow-up endocrinology outpatient appointment is £101. The cost of this activity, as set out in the 2020/21 National Schedule of Costs, is £197. This represents a potential unreimbursed cost to the NHS of £96 per outpatient appointment.

Conference:

Presenting Author: Bolton R

Authors: Higgs K, Halpin C, Bolton R, Frankcom I,

Keywords: gastroenteropancreatic neuroendocrine tumor, lanreotide autogel, home administration, un-reimbursed costs,

#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience

Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, McSweeney A, Furtado O'Mahony L, Quaglia E, John A,

Keywords: homecare,